ZA201400707B - Method for treating schizophrenia - Google Patents

Method for treating schizophrenia

Info

Publication number
ZA201400707B
ZA201400707B ZA2014/00707A ZA201400707A ZA201400707B ZA 201400707 B ZA201400707 B ZA 201400707B ZA 2014/00707 A ZA2014/00707 A ZA 2014/00707A ZA 201400707 A ZA201400707 A ZA 201400707A ZA 201400707 B ZA201400707 B ZA 201400707B
Authority
ZA
South Africa
Prior art keywords
treating schizophrenia
schizophrenia
treating
Prior art date
Application number
ZA2014/00707A
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of ZA201400707B publication Critical patent/ZA201400707B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/88—Unsaturated compounds containing keto groups containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA2014/00707A 2011-08-05 2014-01-29 Method for treating schizophrenia ZA201400707B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161515418P 2011-08-05 2011-08-05
PCT/JP2012/070411 WO2013022079A1 (en) 2011-08-05 2012-08-03 Method for treating schizophrenia

Publications (1)

Publication Number Publication Date
ZA201400707B true ZA201400707B (en) 2014-11-26

Family

ID=47627335

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/00707A ZA201400707B (en) 2011-08-05 2014-01-29 Method for treating schizophrenia

Country Status (18)

Country Link
US (2) US8592483B2 (enExample)
EP (1) EP2739278A4 (enExample)
JP (2) JP6193230B2 (enExample)
KR (1) KR20140076551A (enExample)
CN (2) CN107903173A (enExample)
AR (1) AR087468A1 (enExample)
AU (2) AU2012293157A1 (enExample)
BR (1) BR112014002712A8 (enExample)
CA (1) CA2842455A1 (enExample)
HK (1) HK1252353A1 (enExample)
IL (2) IL230552A (enExample)
MX (1) MX359697B (enExample)
NZ (1) NZ620300A (enExample)
RU (1) RU2648474C2 (enExample)
SG (1) SG10201606442QA (enExample)
TW (2) TWI619497B (enExample)
WO (1) WO2013022079A1 (enExample)
ZA (1) ZA201400707B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103450128B (zh) * 2013-08-15 2015-04-08 河南中帅医药科技股份有限公司 用于治疗青光眼的前列腺素类似物中间体Corey醛的制备方法
US20150057351A1 (en) * 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5428062A (en) 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5591887A (en) 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
CA1324129C (en) 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
ATE82499T1 (de) * 1987-09-18 1992-12-15 R Tech Ueno Ltd Okulare hypotensivagenzien.
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
WO1997047595A1 (en) 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
ITRM20010356A1 (it) * 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
IL157751A0 (en) * 2003-02-28 2004-03-28 Yissum Res Dev Co New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
EP1841433B1 (en) * 2005-01-27 2011-11-30 Sucampo AG Composition for treating central nervous system disorders
AR055038A1 (es) * 2005-03-04 2007-08-01 Sucampo Ag Metodo y compuesto para tratar enfermedades vasculares perifericas
US7211703B2 (en) * 2005-04-27 2007-05-01 Calgon Carbon Corporation Method of separating E and Z isomers of an alkene alcohol and derivatives thereof
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
EP2178516B1 (en) * 2007-07-19 2015-09-09 R-Tech Ueno, Ltd. Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound
WO2012100347A1 (en) * 2011-01-24 2012-08-02 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions

Also Published As

Publication number Publication date
TWI619498B (zh) 2018-04-01
MX359697B (es) 2018-10-08
US8592483B2 (en) 2013-11-26
CN103841966A (zh) 2014-06-04
TW201808302A (zh) 2018-03-16
EP2739278A1 (en) 2014-06-11
US20140031428A1 (en) 2014-01-30
BR112014002712A2 (pt) 2017-06-13
US20130035393A1 (en) 2013-02-07
RU2648474C2 (ru) 2018-03-26
NZ620300A (en) 2015-09-25
CA2842455A1 (en) 2013-02-14
EP2739278A4 (en) 2015-03-18
BR112014002712A8 (pt) 2017-06-20
AU2017203092A1 (en) 2017-06-01
AU2012293157A1 (en) 2014-03-13
MX2014001409A (es) 2014-05-28
AU2017203092B2 (en) 2018-11-08
CN107903173A (zh) 2018-04-13
IL230552A0 (en) 2014-03-31
WO2013022079A1 (en) 2013-02-14
JP2014527048A (ja) 2014-10-09
TW201316992A (zh) 2013-05-01
TWI619497B (zh) 2018-04-01
RU2014108423A (ru) 2015-09-10
IL230552A (en) 2017-09-28
JP2017222708A (ja) 2017-12-21
IL254289A0 (en) 2017-10-31
JP6193230B2 (ja) 2017-09-06
KR20140076551A (ko) 2014-06-20
SG10201606442QA (en) 2016-09-29
HK1252353A1 (zh) 2019-05-24
AR087468A1 (es) 2014-03-26

Similar Documents

Publication Publication Date Title
ZA201400005B (en) Method for treating eczema
PL2685961T3 (pl) Sposób leczenia urazu neurologicznego
EP2698464A4 (en) WASHING METHOD
IL231515A0 (en) Methods for treating hepatitis C virus
EP2760359A4 (en) METHOD FOR TREATING EYE STATES
EP2753275A4 (en) METHODS OF TREATING OCULAR CONDITIONS
ZA201208219B (en) Method for treating wasterwater
IL231495A0 (en) A method for treating osteoporosis
GB201118838D0 (en) Process for treating an underground formation
ZA201400544B (en) Method for treating industrial waste
PL2729233T3 (pl) Sposób kontrolowania mgły
PL2691219T3 (pl) Sposób obróbki tekstyliów technicznych
EP2743258A4 (en) PROCESS FOR PURIFYING LEVO-OXIRACETAM
HRP20130367T1 (hr) Postupak za preradu kože
PL3404041T3 (pl) Sposób leczenia osteoporozy
EP2694077A4 (en) METHOD FOR TREATING ASTHENOPY
EP2723348A4 (en) METHOD FOR THE TREATMENT OF ADIPOSITAS
IL228744A0 (en) A method for treating diseases related to interferon alpha
EP2691104A4 (en) USE OF EZATIOSTAT IN THE TREATMENT OF MULTIPLE MYELOMA
GB201105523D0 (en) Treatment method
ZA201400707B (en) Method for treating schizophrenia
HK1196279A (en) Method for treating schizophrenia
AU2011905367A0 (en) Method for treating liquid